Table 1.
Selected clinical treatments, therapies, and diagnostic tools for liver fibrosis.
| General Category | Target Disease Condition | Therapeutic Agent | Responsible Company/Lab | Phase | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|
| Stem Cells | Compensated Liver Cirrhosis | Autologous Mesenchymal stem cells (MSCs) and Pioglitazone | Royan Institute | Phase I | NCT01454336 [84] |
| Hepatitis C Virus (HCV) Infection | Autologous Mesenchymal stem cells (MSCs) | Saglik Bilimleri Universitesi Gulhane Tip Fakultesi | Phase I/II | NCT02705742 [91] | |
| End-stage Liver Cirrhosis | Autograft MSCs Differentiated Into Progenitor of Hepatocytes | Shahid Beheshti University of Medical Sciences and Tarbiat Modarres University | Phase I/II | NCT00420134 [99] | |
| Chronic liver insufficiency | Autologous Expanded CD34+ Haemopoietic cells | Imperial College London | Phase I/II | NCT00655707 [90] | |
| Liver Cirrhosis | Co-transferring of MSCs and Tregs | Nanjing Medical University | Phase I/II | NCT03460795 [100] | |
| Liver Cirrhosis | Autologous Bone Mesenchymal Stem Cells (bMSCs) via Portal Vein | Sun Yat-sen University | Phase II | NCT00993941 [88] | |
| Acute-On-Chronic Liver Failure | Human umbilical cord-derived mesenchyme stem cells (hUC-MSCs) | Hai Li, Shanghai Jiao Tong University School of Medicine | Phase II | NCT04822922 [101] | |
| Liver Cirrhosis, portal hypertension, hepatic Decompensation | Autologous bone marrow stem cells infusion (ABMSCi) and abdominal portal hypertension surgery | Wenzhou Medical University | Phase II/III | NCT01560845 [86] | |
| Liver Cirrhosis | Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells | Kanazawa University | N/A | NCT01062750 [102] | |
| Small Molecules | Chronic Hepatitis C Virus (HCV) | Small Molecule Agent (PF-868554), direct antiviral agent | Pfizer | Phase I | NCT00671671 [17] |
| Chronic Hepatitis C Virus (HCV) Infection | Emricasan (IDN-6556) | Conatus Pharmaceuticals Inc. | Phase II | NCT02138253 [103] | |
| Chronic Liver Fibrosis | Prolonged-Release Pirfenidone Formulation | Grupo Mexicano para el Estudios de las Enfermedades Hepaticas | Phase II | NCT04099407 [104] | |
| Hepatic Fibrosis in Chronic Hepatitis C | Irbesartan | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) and Sanofi | Phase III | NCT00265642 [105] | |
| Hepatic Fibrogenesis in Chronic Hepatitis C | Losartan | Hospital Clinic of Barcelona | Phase IV | NCT00298714 [106] | |
| Antibody Therapy | Alcoholic Liver Disease | Guselkumab, a humanized anti-IL23 monoclonal antibody | University of California, San Diego | Phase I | NCT04736966 [107] |
| Non-alcoholic Fatty Acid Liver Disease | IMM-124E, polyclonal antibody against endotoxin lipopolysaccharide (LPS) | Immuron Ltd., Emory University, and Advanced MR Analytics AB | Phase II | NCT03042767 [108] | |
| Diagnostic Tools | Liver Fibrosis and Congestion in Fontan Patients | Non-Contrast Magnetic Resonance Imaging, Device | Children’s Hospital Medical Center, Cincinnati | N/A | NCT03539757 [109] |
| Liver Fibrosis | Mechanical Vibrations with Ultrasound Shear Wave Imaging, Device | Mayo Clinic | N/A | NCT03637959 [110] | |
| Liver Fibrosis | Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens, Device | University Hospital, Grenoble & Clinical Investigation Centre for Innovative Technology Network | N/A | NCT01537965 [111] |